

Investor Relations FAQ Sheet:

Thank you for your interest in Angiotech. For further and detailed information with respect to the condition of our business, including potential risk factors, we encourage you to refer to our most recent filings, including but not limited to our annual report on form 10-K for the year ended December 31, 2010, as well as our most recent quarterly report on form 10-Q, which can be accessed through our website at www.angiotech.com.

- 1. It looks like Angiotech just completed a debt restructuring process, and filed court proceedings as a result. Can you explain that process?** Angiotech in May of 2011 completed a recapitalization transaction, resulting in a reduction of the Company's long-term debt obligations by \$250 million. This transaction significantly improved the Company's liquidity, working capital and capital resources. To facilitate the completion of this transaction, the Company was required to undertake certain court proceedings in British Columbia, Canada and in the United States. These proceedings, which are often referred to as "debt restructurings" or a "pre-packaged bankruptcy," are typical steps that companies at times are required to take in order to restructure and eliminate certain of their debt obligations, often as a result of material changes that have impacted operations, cash flows and liquidity in their businesses. Angiotech's need to pursue such a transaction was preceded by a significant decline in royalty revenue received from one of our corporate partners. Importantly, Angiotech's most significant ongoing business operations, in particular our medical products businesses in the areas of general surgery, biopsy and interventional radiology and other medical device components, were not materially impacted by this process, and we continue to supply our customers with our products as we have in the past.
- 2. Have Angiotech's business operations been materially impacted by this restructuring?** No. While some minor operational changes were implemented as part of the recapitalization transaction to better position Angiotech's business for the future, our major medical products sales, manufacturing and other related initiatives were not materially impacted by this process, and we expect to continue to operate our business as usual. Importantly, we believe the recapitalization transaction, by enabling improvements in our credit profile, liquidity and capital resources, strengthens our competitive position and business initiatives as we look to our future.
- 3. Have there been any changes to Angiotech's product portfolio? What are Angiotech's key businesses and product lines?** Our most important product lines and businesses continue to be in the areas of wound closure, biopsy, interventional radiology, ophthalmology and medical device components. There have been no material changes to the Company's product portfolio, with one exception - as part of the recapitalization transaction, we no longer sell the Option IVC filter product line, for which we had licensed rights from a corporate partner.
- 4. What is the future outlook for Angiotech's business?** We believe, with the completion of our recent recapitalization transaction, and the elimination of \$250 million of long-term debt and improved liquidity and financial flexibility, that the outlook for our business is improved. We are encouraged that most of our significant lines of business

remained stable or continued to exhibit revenue growth during the latest three month and 12 month periods.

- 5. Does Angiotech have sufficient cash and liquidity to fund its business going forward?** With the completion of our recapitalization transaction, we eliminated \$250 million of long-term debt obligations and the fixed annual cash interest expenses related thereto. As a result, we have improved our liquidity, working capital and capital resources available to invest in and support our business initiatives. There can be no assurance however that certain risk factors relating to our business will not impact our levels of liquidity and cash resources in the future, and we still have significant long-term debt outstanding even after the completion of the recapitalization.
- 6. What is the future of the Company's royalty business? What is the future outlook for the TAXUS® and Zilver™ PTX™ stents?** We continue to receive royalties from partners, most substantially from our partner Boston Scientific Corporation relating to their sales of TAXUS drug-eluting coronary stents. In addition, our partner Cook Medical has submitted a request for approval of their Zilver-PTX drug-eluting peripheral vascular stent in the United States, and has received approval to sell Zilver-PTX in the European Union and other countries outside of the United States. We also receive royalties derived from sales of Zilver-PTX by Cook Medical. While we expect royalty revenue will continue to contribute to our cash flows for the foreseeable future, there can be no assurances that our partners will continue to sell products from which we derive royalties, or that they will achieve sales levels consistent with past periods, or receive or maintain required regulatory approvals to sell these products.
- 7. What is the future outlook for Quill™? For the other innovations of the Company?** Our proprietary Quill product line, which enables surgeons to close wounds in various surgical procedures with no need to tie knots, continues to be a significant and important product franchise for Angiotech. We expect that Quill will continue to be a significant part of our business, and we continue to develop new Quill technology and intellectual property through our significant research and development efforts. In addition, we continue to periodically develop and introduce new technologies across our various medical products businesses, and maintain research capabilities relating to potential new product opportunities in drug-eluting medical devices and drug delivery primarily for surgical applications.
- 8. ANPI (NASDAQ), ANP (TSE) and ANPIQ (OTCBB) are no longer valid codes. Does Angiotech have publicly traded shares?** As part of our recent recapitalization of the Company, we exchanged 100% of our subordinated debt obligations for 100% of the common equity ownership in the Company. The new common shares that were issued to the holders of our subordinated debt are private shares, and are not currently listed for trading on any exchange, including those noted above.
- 9. I was an owner of Angiotech old common shares. Is it the case that these shares no longer have any value?** As an inducement for our subordinated noteholders to forgive the debts owed to them by the Company, it was necessary to exchange their holdings of this debt for all of the ownership of new common shares in Angiotech. Given the Company's significant liquidity issues and our likely inability to continue to pay interest due on our subordinated debt, this recapitalization transaction was required. As a result, of this recapitalization transaction, our old common shares were cancelled and

no longer have any value. While this is a difficult situation for our old common shareholders, this is a typical restructuring approach companies must undertake when they experience significant difficulties in their business that impact their ability to repay their debts.

- 10. Why do debt holders get all of the common stock? Why is there no consideration for shareholders?** According to the laws that typically govern corporate debt obligations, a company's creditors must be paid what is owed to them before common shareholders of a company are entitled to any consideration. When a company runs into severe difficulties or experiences unexpected rapid changes to its business (as Angiotech did in its royalty business) and cannot adequately service or repay all its debts, the company's creditors are often provided with full ownership of a company's common shares as consideration for the debts owed. That is what happened in Angiotech's case, similar to the outcomes observed in many other recent restructuring transactions including GM, Canwest Media, Six Flags, MGM and many others.
- 11. Can I ever expect to get anything from my shares?** Unfortunately no, there will be no future consideration offered to Angiotech's old common shareholders. This unfortunate but necessary outcome was a condition of our recapitalization that allowed Angiotech to continue as a going concern with a reduced debt burden. Many companies experience rapid change or unexpected shocks to their business as a result of many risk factors, and in those situations common shareholders can often experience significant losses.
- 12. In the past, I have had shares with other companies that filed for bankruptcy but we still own shares. Can you please explain?** In the significant majority of recapitalization transactions of the type completed by Angiotech, all of a company's old common shares are cancelled. In a smaller number of recapitalization or restructuring transactions, some portion of common share ownership may be retained for existing common shareholders at the time of the transaction, depending upon the magnitude of the obligations being restructured as compared to the overall valuation of the company in question. While your brokerage account statements may still indicate you own old Angiotech common shares, 100% of those shares have been cancelled as a condition of our recapitalization transaction. As a result, those shares no longer exist within our corporate structure. They may still be listed on your brokerage account statement as an administrative matter in order for you to be able to accurately account for any tax losses incurred with respect to ownership of old Angiotech common shares.
- 13. Will Angiotech ever have public shares or complete an IPO in the future? Where can I buy shares in the restructured company?** Depending on the progress of our business plans and other factors, we may elect to list Angiotech shares in an Initial Public Offering or other similar transaction. At present, we have no specific plans to do so. The Company's new common shares are held primarily by the holders of the 7.75% Subordinated Notes that were retired as a result of our recapitalization transaction. These new common shares do not trade on any public exchange, and may only trade in privately negotiated transactions among Qualified Institutional Buyers as defined by United States Securities laws, subject to applicable rules and regulations.

- 14. Will Angiotech still file disclosure documents with the regulatory agencies? What about press releases for quarterly earnings or other events?** Angiotech will continue to file required quarterly, annual and other disclosures with the United States Securities and Exchange Commission (including quarterly and annual reports on forms 10-Q and 10-K respectively). Angiotech expects to continue to conduct conference calls on a quarterly basis to discuss business and financial results. Angiotech is no longer required to file similar documents in Canada.
- 15. It seems there is still significant debt outstanding on Angiotech's balance sheet. How does Angiotech intend to address its remaining debt obligations?** With the completion of our recapitalization transaction in May 2011, we reduced our long-term debt obligations by \$250 million, leaving \$325 million in remaining long-term debt with a maturity date in late 2013. We believe the recapitalization provides for a pro forma credit profile that effectively positions Angiotech to address its remaining long-term debt obligations, in particular when considering the significant and historically stable revenue and stable to improved operating margins and cash flows generated by our medical products businesses. There can be no assurances, however, that Angiotech's business condition, liquidity or operating cash flows will be sufficient for Angiotech to refinance or repay its remaining debt obligations when they become due.
- 16. Who should I contact if I have additional questions?** Please contact our investor relations hotline. The e-mail address is ir@angio.com. For further comment with respect to the condition of our business, including potential risk factors, we encourage you to refer to our most recent filings, including but not limited to our annual report on form 10-K for the year ended December 31, 2010, as well as our most recent quarterly report on form 10-Q, which can be accessed through our website at www.angiotech.com.